FoldRx, Pfizer deal

Pfizer will acquire FoldRx for an undisclosed upfront payment plus potential milestones. Pfizer gains FoldRx's lead candidate, tafamidis, a small molecule that stabilizes transthyretin (TTR) protein and prevents misfolding. The compound is under review in Europe to treat TTR amyloid polyneuropathy (ATTR-PN) or familial amyloid polyneuropathy (FAP). Tafamidis has Orphan Drug designation in the U.S. and EU as well as Fast Track designation in the U.S. Pfizer also gains FoldRx's yeast-based drug target discovery programs for cystic fibrosis (CF), Parkinson's disease (PD) and Huntington's disease (HD). ...